Marengo Therapeutics’ bispecific immuno-oncology agent invikafusp alfa (STAR0602) won an expanded FDA fast track designation across TMB-H solid tumors after prior therapy, including patients previously treated with checkpoint inhibitors. The update broadens its earlier tissue-specific fast track status in TMB-H colorectal cancer.